Boston Scientific gains approval for asthma device in China

10/25/2013 | (Boston)

Chinese regulators have granted Boston Scientific approval to market its Alair Bronchial Thermoplasty device in that country. The device, which the company acquired through its $193.5 million purchase of Asthmatx in 2010, is designed to treat severe asthma patients who have failed to respond to long-acting beta-agonists or inhaled corticosteroids.

View Full Article in: (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care